ADAM17 and neoplasm: Human NK cells expressing a non-cleavable version of CD16A or upon blocking ADAM17 activity demonstrated increased killing of tumor cells by ADCC and production of IFNγ (5–7), and thus this may be an approach to enhance ADCC by CD16A+ canine lymphocytes.